Ryvu Therapeutics SA Asset Resilience Ratio

Latest as of March 2026: 16.62%

Ryvu Therapeutics SA asset resilience ratio. Ryvu Therapeutics SA (RVU) has an Asset Resilience Ratio of 16.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RVU defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

zł33.40 Million
≈ $9.19 Million USD Cash + Short-term Investments

Total Assets

zł200.96 Million
≈ $55.31 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Ryvu Therapeutics SA (2011–2025)

Asset resilience ratio of Ryvu Therapeutics SA from 2011 to 2025. This chart shows how Ryvu Therapeutics SA's Asset Resilience Ratio has changed over time. Read RVU total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Ryvu Therapeutics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RVU total asset value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents zł0.00 0%
Short-term Investments zł33.40 Million 16.62%
Total Liquid Assets zł33.40 Million 16.62%

Asset Resilience Insights

  • Good Liquidity Position: Ryvu Therapeutics SA maintains a healthy 16.62% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Ryvu Therapeutics SA Industry Peers by Asset Resilience Ratio

Compare Ryvu Therapeutics SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 36.07%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
3SBio Inc
F:83B
Biotechnology 10.64%

Ryvu Therapeutics SA Asset Resilience Ratio by Year (2011–2025)

Ryvu Therapeutics SA asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Ryvu Therapeutics SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 21.42% zł48.07 Million
≈ $13.23 Million
zł224.44 Million
≈ $61.77 Million
+4.03pp
2024-12-31 17.39% zł65.86 Million
≈ $18.12 Million
zł378.78 Million
≈ $104.24 Million
-26.20pp
2023-12-31 43.58% zł175.73 Million
≈ $48.36 Million
zł403.20 Million
≈ $110.97 Million
+43.47pp
2022-12-31 0.11% zł528.00K
≈ $145.31K
zł474.98 Million
≈ $130.72 Million
-2.07pp
2021-12-31 2.18% zł4.99 Million
≈ $1.37 Million
zł228.81 Million
≈ $62.97 Million
-6.26pp
2020-12-31 8.45% zł24.97 Million
≈ $6.87 Million
zł295.64 Million
≈ $81.36 Million
+8.52pp
2018-12-31 -0.08% zł-196.04K
≈ $-53.95K
zł255.70 Million
≈ $70.37 Million
+0.11pp
2017-12-31 -0.19% zł-196.04K
≈ $-53.95K
zł103.57 Million
≈ $28.50 Million
-0.64pp
2014-12-31 0.45% zł120.00K
≈ $33.03K
zł26.80 Million
≈ $7.38 Million
-0.22pp
2013-12-31 0.67% zł120.00K
≈ $33.03K
zł17.98 Million
≈ $4.95 Million
+1.72pp
2012-12-31 -1.06% zł-162.04K
≈ $-44.60K
zł15.35 Million
≈ $4.22 Million
-0.50pp
2011-12-31 -0.56% zł-98.08K
≈ $-26.99K
zł17.50 Million
≈ $4.82 Million
--
pp = percentage points

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology
Market Cap
$104.61 Million
zł380.10 Million PLN
Market Cap Rank
#18790 Global
#144 in Poland
Share Price
zł16.44
Change (1 day)
-2.26%
52-Week Range
zł13.76 - zł29.90
All Time High
zł75.00
About

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myel… Read more